Literature DB >> 22767877

Air travel and chronic obstructive pulmonary disease: a new algorithm for pre-flight evaluation.

Anne Edvardsen1, Aina Akerø, Carl C Christensen, Morten Ryg, Ole H Skjønsberg.   

Abstract

BACKGROUND: The reduced pressure in the aircraft cabin may cause significant hypoxaemia and respiratory distress in patients with chronic obstructive pulmonary disease (COPD). Simple and reliable methods for predicting the need for supplemental oxygen during air travel have been requested.
OBJECTIVE: To construct a pre-flight evaluation algorithm for patients with COPD.
METHODS: In this prospective, cross-sectional study of 100 patients with COPD referred to hypoxia-altitude simulation test (HAST), sea level pulse oximetry at rest (SpO(2 SL)) and exercise desaturation (SpO(2 6MWT)) were used to evaluate whether the patient is fit to fly without further assessment, needs further evaluation with HAST or should receive in-flight supplemental oxygen without further evaluation. HAST was used as the reference method.
RESULTS: An algorithm was constructed using a combination of SpO(2 SL) and SpO(2 6MWT). Categories for SpO(2 SL) were >95%, 92-95% and <92%, the cut-off value for SpO(2 6MWT) was calculated as 84%. Arterial oxygen pressure (PaO(2 HAST)) <6.6 kPa was the criterion for recommending supplemental oxygen. This algorithm had a sensitivity of 100% and a specificity of 80% when tested prospectively on an independent sample of patients with COPD (n=50). Patients with SpO(2 SL) >95% combined with SpO(2 6MWT) ≥84% may travel by air without further assessment. In-flight supplemental oxygen is recommended if SpO(2 SL)=92-95% combined with SpO(2 6MWT) <84% or if SpO(2 SL) <92%. Otherwise, HAST should be performed.
CONCLUSIONS: The presented algorithm is simple and appears to be a reliable tool for pre-flight evaluation of patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22767877     DOI: 10.1136/thoraxjnl-2012-201855

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Cardiorespiratory Adaptation to Short-Term Exposure to Altitude vs. Normobaric Hypoxia in Patients with Pulmonary Hypertension.

Authors:  Simon R Schneider; Mona Lichtblau; Michael Furian; Laura C Mayer; Charlotte Berlier; Julian Müller; Stéphanie Saxer; Esther I Schwarz; Konrad E Bloch; Silvia Ulrich
Journal:  J Clin Med       Date:  2022-05-14       Impact factor: 4.964

2.  Low oxygen saturation and mortality in an adult cohort: the Tromsø study.

Authors:  Monica Linea Vold; Ulf Aasebø; Tom Wilsgaard; Hasse Melbye
Journal:  BMC Pulm Med       Date:  2015-02-12       Impact factor: 3.317

3.  Low FEV1, smoking history, and obesity are factors associated with oxygen saturation decrease in an adult population cohort.

Authors:  Monica Linea Vold; Ulf Aasebø; Hasse Melbye
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-10-21

4.  Pre-flight evaluation of adult patients with cystic fibrosis: a cross-sectional study.

Authors:  Elisabeth Edvardsen; Aina Akerø; Ole Henning Skjønsberg; Bjørn Skrede
Journal:  BMC Res Notes       Date:  2017-02-06

5.  Are pulmonologists well aware of planning safe air travel for patients with COPD? The SAFCOP study.

Authors:  Begüm Ergan; Hüseyin Arıkan; Metin Akgün
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-08-22

6.  BTS Clinical Statement on air travel for passengers with respiratory disease.

Authors:  Robina Kate Coker; Alison Armstrong; Alistair Colin Church; Steve Holmes; Jonathan Naylor; Katharine Pike; Peter Saunders; Kristofer John Spurling; Pamela Vaughn
Journal:  Thorax       Date:  2022-02-28       Impact factor: 9.139

7.  Assessing Patients for Air Travel.

Authors:  Amy L Bellinghausen; Jess Mandel
Journal:  Chest       Date:  2020-11-16       Impact factor: 9.410

8.  Should pulse oximetry be included in GPs' assessment of patients with obstructive lung disease?

Authors:  Lene G Dalbak; Jørund Straand; Hasse Melbye
Journal:  Scand J Prim Health Care       Date:  2015-12-11       Impact factor: 2.581

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.